The conclusions were that the short regimen is adequate for group I patients without the use of RT and that the addition of doxorubicin improves outcome in all other stages, particularly those with favorable histology.
D'Angio GJ, Breslow N, Beckwith JB, Evans A, Baum H, deLorimier A, Fernbach D, Hrabovsky E, Jones B, Kelalis P. Treatment of Wilms' tumour. Results of the Third National Wilms' Tumor Study. Cancer 1989; 64:349-60.
The study was carried out between 1979 and 1985 by the National Wilms' Tumor Study Group (NWTS-3).
Was this article helpful?